Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.62

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. COIN
4. PINS
5. RDDT
6. FSLR
7. SYK
8. DASH
9. SBUX
10. SNDK

Go back to Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.62

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

March 27, 2019 4:05 PM EDT

Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT

BERKELEY HEIGHTS, N.J., March 27, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results and business highlights for the fourth quarter and full year ended December 31, 2018.  The Company's net loss applicable to common shareholders for the three months and year ended December 31, 2018 was $2.1 million and $7.5 million, respectively.  As of December 31, 2018, cash and cash equivalents totaled $17.5 million, not including net proceeds of approximately $4.1 million... More